Urology cancer symposium

Date

Friday 22 April 2016

Day

Venue Royal Society of Medicine
1 Wimpole Street
LONDON
W1G 0AE
Organised by

Urology Section

Accreditation

6 CPD points

Event Image

about this event

Attendees will hear and interact with national and International experts who will cover much of the urological oncology syllabus, particularly those aspects not covered at the recent BAUS annual scientific meeting. It will provide an update to trainee and established urologists with discussion of “breaking news” in the treatment of prostate, bladder, renal and testis cancer and especially provide new guidance on the management of superficial bladder cancers and the modern management of lymph nodes in prostatic and testis cancers. 

This exciting meeting has been designed by the Section of Urology of the RSM to cover most of the urological oncology syllabus, particularly those aspects not covered at the recent BAUS annual scientific meeting. It will therefore be of particular interest to urological trainees at all levels and also to the Oncology Section and to oncology trainees and trained doctors generally. North and South London urology trainees are expected to attend this meeting as part of their official training programme.

Limited subsidised places are available to trainees, please contact urology@rsm.ac.uk to secure your place today.

 

agenda

8.45 am

Registration, tea and coffee

Session one: Prostate

Professor Roger Kirby, Professor of Urology, The Prostate Centre

9.15 am

Introduction

Professor Tom McNicholas, President of Urology Section, Royal Society of Medicine and Professor Nick James, Professor of Oncology, The Queen Elizabeth Hospital Birmingham and The Cancer Research Unit, University of Warwick

9.25 am

Classifying surgical candidates for radical prostatectomy

Mr Jim Adshead, Consultant Urological Surgeon, Hertfordshire and Bedfordshire Urological Cancer Centre

9.45 am

The role of surgery for high-risk and oligo-metastatic prostate cancer

Professor Steven Joniau, Urology Department, University Hospitals Leuven

10.05 am

Hormone-sensitive prostate cancer

Professor Nick James, Professor of Oncology, The Queen Elizabeth Hospital Birmingham and The Cancer Research Unit, University of Warwick

10.25 am

Biomarkers for treatment selection

Dr Gerhardt Attard, Clinician Scientist at The Institute of Cancer Research, London, and Honorary Consultant at The Royal Marsden NHS Foundation Trust

10.45 am

Debate: Should urologists be administering new medical therapies for prostate cancer?

Yes

Professor Steven Joniau, Urology Department, University Hospitals Leuven

No

Dr Simon Crabb, Associate Professor in Medical Oncology, University of Southampton

11.05 am

Open debate and panel discussion on all topics above

11.15 am

Tea and coffee break

Session two: Bladder

Mr Rik Bryan, Senior Research Fellow, Institute for Cancer and Genomic Sciences, University of Birmingham

11.30 am

The Bladder Path trial

Professor Nick James, Professor of Oncology, The Queen Elizabeth Hospital Birmingham and The Cancer Research Unit, University of Warwick

11.50 am

En bloc transurethral resection - the future for TURBT?

Mr James Douglas, Consultant Urological Surgeon, University Hospital Southampton NHS Foundation Trust

12.10 pm

Has our infatuation with BCG hampered progress?

Mr Prashant Patel, Consultant Urological Surgeon and Senior Lecturer, University Hospitals Birmingham NHS Foundation Trust and The University of Birmingham

12.30 pm

Debate: Adjuvant versus neoadjuvant chemotherapy

Neoadjuvant

Dr Simon Crabb, Associate Professor in Medical Oncology, University of Southampton

Adjuvant

Dr Maria de Santis, Associate Clinical Professor of Oncology, University of Warwick

12.50 pm

Open debate and panel discussion on all topics above

1.00 pm

Lunch

Session three: Kidney

Mr Damian Hanbury, Consultant Urological Surgeon and ex member of EAU Renal cancer Guideline Committee, The Lister Hospital

2.00 pm

The role of the NCRI clinical studies groups

Dr James Larkin, Medical Oncologist, Royal Marsden Hospital, London

2.20 pm

Nephron sparing surgery

Mr Jim Adshead, Consultant Urological Surgeon, Hertfordshire and Bedfordshire Urological Cancer Centre

2.40 pm

Nivolumab

Dr James Larkin, Medical Oncologist, Royal Marsden Hospital, London

3.00pm

Tea and coffee break

Session four: Testis

Professor Nick James, Professor of Oncology, The Queen Elizabeth Hospital Birmingham and The Cancer Research Unit, University of Warwick

3.15 pm

RPLND in the robotic era

Mr Tim Dudderidge, Consultant Urological Surgeon, University Hospital Southampton NHS Foundation Trust

3.35 pm

Second line therapy and the TIGER trial

Professor Rob Huddart, Professor of Urological Oncology, The Institute of Cancer Research

3.55 pm

Long-term adverse health outcomes among survivors of testicular cancer aged 15-39 years

Dr Raoul Reulen, Senior Lecturer and NIHR Fellow, Institute of Applied Health Research, University of Birmingham

4.25 pm

Open debate and panel discussion on all topics above and summary of meeting

Professor Tom McNicholas and Professor Nick James

4.40 pm

Completion of evaluation forms

4.45 pm

Close of meeting

register for this event

  • Online registration is now closed
  • You can register on the day for this meeting, please be aware lunch may not be provided to those who register on the day

rates

View rates for all membership types:

View rates

organiser's details

For information on this event, contact Faye KelleherTel: 02072902987 Fax: 02072902989 Email: urology@rsm.ac.uk arrow